Bergen, Norway, 25 April 2024 - Reference is made to the stock exchange
announcement by BerGenBio ASA (the "Company") on 16 April 2024 regarding the
final results of the last exercise period for the warrants ("Warrants") issued
in connection with the rights issue, which resulted in an allocation of
1,106,565,434 new shares in the Company ("New Shares") to investors holding
Warrants. A reference is also made to the stock exchange announcement by
BerGenBio ASA on 17 April 2024 regarding an increase of the Company's share
capital by issuance of 113,456,919 new shares in connection with settlement of
underwriting commission in accordance with underwriting agreements dated 1 April
2024 and made by and between the Company and the underwriters (the "Fee
Shares").

The share capital increases pertaining to the New Shares and the Fee Shares are
now registered with the Norwegian Register of Business Enterprises. After this,
the Company's new registered share capital is NOK 390,871,156.70 divided into
3,908,711,567 shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.